Abstract

Liver fatty acid-binding protein (L-FABP), also known as fatty acid-binding protein 1 (FABP1), is a key regulator of hepatic lipid metabolism. Elevated FABP1 levels are associated with an increased risk of cardiovascular disease (CVD) and metabolic syndromes. In this study, we examine the association of FABP1 gene promoter variants with serum FABP1 and lipid levels in a Chinese population. Four promoter single-nucleotide polymorphisms (SNPs) of FABP1 gene were genotyped in a cross-sectional survey of healthy volunteers (n = 1,182) from Fuzhou city of China. Results showed that only the rs2919872 G>A variant was significantly associated with serum TG concentration(P = 0.032).Compared with the rs2919872 G allele, rs2919872 A allele contributed significantly to reduced serum TG concentration, and this allele dramatically decreased the FABP1 promoter activity(P < 0.05). The rs2919872 A allele carriers had considerably lower serum FABP1 levels than G allele carriers (P < 0.01). In the multivariable linear regression analysis, the rs2919872 A allele was negatively associated with serum FABP1 levels (β = —0.320, P = 0.003), while serum TG levels were positively associated with serum FABP1 levels (β = 0.487, P = 0.014). Our data suggest that compared with the rs2919872 G allele, the rs2919872 A allele reduces the transcriptional activity of FABP1 promoter, and thereby may link FABP1 gene variation to TG level in humans.

Highlights

  • Clinical lipid disorders are associated with enormous public health significance and increasing societal burden in many countries [1]

  • We investigated the common polymorphisms located in the promoter region of the fatty acid-binding protein 1 (FABP1) gene that may affect lipid metabolism by influencing FABP1 gene transcription

  • In this study, decreased levels of serum FABP1 were observed in subjects with the rs2919872 A allele, indicating that a G>A transition at rs2919872, which is located in the promoter region of the FABP1 gene is responsible for a major effect on serum TG levels in a Chinese Han population

Read more

Summary

Introduction

Clinical lipid disorders are associated with enormous public health significance and increasing societal burden in many countries [1]. Epidemiological evidence supporting raised plasma triglycerides (TG) is emerging as an independent risk factor for Type 2 diabetes, fatty liver, metabolic syndrome and atherosclerotic cardiovascular disease (CVD) [2,3,4]. The concentration of PLOS ONE | DOI:10.1371/journal.pone.0139417. Human FABP1 Promoter Polymorphism and TG Levels. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call